Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Other Non-Current Assets (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Other Non-Current Assets for 9 consecutive years, with $287000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 27.56% to $287000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $287000.0 through Dec 2025, up 27.56% year-over-year, with the annual reading at $287000.0 for FY2025, 27.56% up from the prior year.
  • Other Non-Current Assets hit $287000.0 in Q4 2025 for Protagonist Therapeutics, roughly flat from $287000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $290000.0 in Q2 2025 to a low of $225000.0 in Q1 2021.
  • Historically, Other Non-Current Assets has averaged $234450.0 across 5 years, with a median of $225000.0 in 2021.
  • Biggest five-year swings in Other Non-Current Assets: crashed 50.0% in 2021 and later grew 28.89% in 2025.
  • Year by year, Other Non-Current Assets stood at $225000.0 in 2021, then changed by 0.0% to $225000.0 in 2022, then changed by 0.0% to $225000.0 in 2023, then changed by 0.0% to $225000.0 in 2024, then grew by 27.56% to $287000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for PTGX at $287000.0 in Q4 2025, $287000.0 in Q3 2025, and $290000.0 in Q2 2025.